Brand-Name Vs. Generic Drug Brands

When you’re paying for your drugs it’s hard to know what you’re actually paying for.

Are you buying the chemical compounds contained in the pill? Are you buying the research and development that was necessary to bring the pill to market? Or are you buying the brand name printed on the bottle?

The pharmaceutical industry is big business, but it’s no sure bet. It requires much time and huge investments to research, develop and market drugs. Since there’s more economic value in the proprietary research and formulation of a successful drug, than in the raw materials, drug companies often fight patent wars.

This pits the drug manufacturers who developed the drugs against generic manufacturers who lay in wait for patents to expire so they can produce the same drug, but undercut the competition with cheaper prices. After all, generic manufacturers spend far less on R&D so they can afford to sell their product at a cheaper price.

I found an interesting trend when comparing the stock price of Bristol-Myers Squibb (NYSE: BMY) – a major, brand-name manufacturer – against the stock price of Mylan (NYSE: MYL) – a generic drug maker.

This chart shows the relative performance of these two companies, by dividing Mylan’s stock price by Bristol-Myers Squibb’s.

See image larger

As the chart moves higher, it indicates that Mylan is outperforming Bristol-Myers. And as you can see, that’s the general trend ever since the market bottomed in early 2009.

This may or may not be an industry-wide trend, but it will be interesting to see how the battle plays out between drug makers with significant R&D costs and the generic makers that can offer the same chemicals at cheaper prices once the patent has expired.

If you haven’t done so already read the Survive & Prosper issue on “Pharmaceutical Companies Are Happy – Old People Are Buying Drugs.”

 

 

Harry Dent’s Most Disturbing Prediction in Years

Harry Dent, one of the most respected economists in the industry, has uncovered a disturbing market event that could soon devastate millions of investors. In short, he has undeniable proof that one of the market’s safest and most popular investments is about to get slaughtered… and it will have dire consequences for those who don’t prepare right away.

For full details on the event Harry’s dubbed as the “Safe-Asset Slaughter”… and to ensure you escape the coming carnage, I urge you to watch this special presentation.

Click to Learn More
Categories: Economy

About Author

Adam O'Dell has one purpose in mind: to find and bring to subscribers investment opportunities that return the maximum profit with the minimum risk. Adam has worked as a Prop Trader for a spot Forex firm. While there, he learned the fundamentals of trading in the world’s largest market. He excelled at trading the volatile currency markets by seeking out low-risk entry points for trades with high profit potential. An MBA graduate and Affiliate Member of the Market Technicians Association, Adam is a lifelong student of the markets. He is editor of our hugely successful trading service, Cycle 9 Alert.